AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
165 hedge funds and large institutions have $1.03B invested in AMAG Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 62 increasing their positions, 57 reducing their positions, and 36 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
9% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 57
3% more capital invested
Capital invested by funds: $1B → $1.03B (+$29.1M)
11% less funds holding
Funds holding: 185 → 165 (-20)
44% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 36
99% less call options, than puts
Call options by funds: $2.04M | Put options by funds: $188M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$17.9M |
| 2 |
GCM
Greywolf Capital Management
Purchase,
New York
|
+$15.2M |
| 3 |
Morgan Stanley
New York
|
+$13.5M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$12.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$36.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$16.8M |
| 3 |
D.E. Shaw & Co
New York
|
-$14.4M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$11.4M |
| 5 |
SIM
Stelliam Investment Management
New York
|
-$8.6M |
AMAG Hedge Fund Activity: Q2 2016 in Review
165 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2016, worth a combined $1.03B — up 2.9% from $1B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of AMAG and 20 opened new positions — a net loss of 16 holders — while 57 trimmed existing stakes and 62 added.
The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $17.9M. The largest seller was Putnam Investments, cutting an estimated $36.2M.
- 165 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2016, down from 185 in Q1 2016.
- Funds reported $1.03B of AMAG Pharmaceuticals stock for Q2 2016, up 2.9% quarter-over-quarter.
- 20 funds opened new AMAG Pharmaceuticals positions in Q2 2016 and 36 closed out, a net change of -16 holders.
- The largest AMAG Pharmaceuticals buyer in Q2 2016 was EverPoint Asset Management, an estimated $17.9M added.
- The largest AMAG Pharmaceuticals seller in Q2 2016 was Putnam Investments, an estimated $36.2M sold.
Based on aggregated 13F filings for Q2 2016.